Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.
OBJECTIVE
Peroxisome proliferator-activated receptor-γ (PPAR-γ) is a ligand-activated transcription factor, implicated in various aspects of cancer biology, such as differentiation, proliferation, invasion and angiogenesis. The present study aimed to evaluate the clinical significance of PPAR-γ in mobile tongue squamous cell carcinoma (SCC).


METHODS
PPAR-γ protein expression was assessed immunohistochemically on 49 mobile tongue SCC tissue samples obtained from an equal number of patients. PPAR-γ expression and intensity of immunostaining were statistically analyzed in relation with clinicopathological characteristics, mitotic index and patients' survival.


RESULTS
Elevated PPAR-γ expression was more frequently observed in patients with reduced depth of invasion (P = 0.0111). Moderate/intense PPAR-γ staining intensity was more frequently observed in patients with no evidence of muscular infiltration (P = 0.0229) and reduced depth of invasion (P = 0.0176). Mobile tongue SCC patients presenting enhanced PPAR-γ expression had significantly longer overall and disease-free survival times compared to those with low PPAR-γ expression (log-rank test, P = 0.0162 and P = 0.0114, respectively).


CONCLUSIONS
PPAR-γ immunoreactivity in mobile tongue SCC was correlated with clinicopathological characteristics crucial for patients' management and prognosis. PPAR-γ may be considered as a useful prognostic marker in mobile tongue SCC and a potential therapeutic target for tongue cancer chemoprevention and treatment.
Theocharis
Stamatios
S
Department of Pathology, Head and Neck Surgery, Institut Curie, Paris, France. theocharis@ath.forthnet.gr
Klijanienko
Jerzy
J
Giaginis
Constantinos
C
Rodriguez
Jose
J
Jouffroy
Thomas
T
Girod
Angelique
A
Point
Daniel
D
Tsourouflis
Gerasimos
G
Satre-Garau
Xavier
X
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005927:Glossectomy; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D037981:Neck Dissection; D009361:Neoplasm Invasiveness; D047495:PPAR gamma / Q000032:analysis*; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D014062:Tongue Neoplasms / Q000737:chemistry* / Q000401:mortality* / Q000473:pathology / Q000601:surgery
D014408:Biomarkers, Tumor; D047495:PPAR gamma
Head Neck. 2002 Jun;24(6):513-20
12112547
Mol Cell. 1999 Jun;3(6):799-804
10394368
Cancer. 1995 Apr 1;75(7):1649-56
8826923
Biochim Biophys Acta. 2007 Aug;1771(8):952-60
17560826
Cancer Metastasis Rev. 2007 Dec;26(3-4):645-62
17768600
Lancet. 2002 Oct 12;360(9340):1131-5
12387961
Med Sci Monit. 2009 May;15(5):BR148-56
19396032
Am J Surg. 2000 Aug;180(2):139-43
11044531
Am J Surg Pathol. 2005 Feb;29(2):167-78
15644773
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
Histopathology. 2005 Jan;46(1):37-42
15656884
Cancer Metastasis Rev. 2005 Jan;24(1):9-17
15785869
Mod Pathol. 2003 Dec;16(12):1218-23
14681322
Dig Dis Sci. 2007 Sep;52(9):2305-11
17393321
Eur J Surg Oncol. 2009 Feb;35(2):197-201
18513919
PPAR Res. 2008;2008:431763
18464916
Cancer Metastasis Rev. 2005 Jan;24(1):107-27
15785876
J Cancer Res Clin Oncol. 2009 Nov;135(11):1551-9
19495794
ANZ J Surg. 2009 Jan-Feb;79(1-2):19-22
19183373
Int J Oncol. 2001 Sep;19(3):465-71
11494023
Cell Cycle. 2007 Jul 1;6(13):1539-48
17611413
Oral Oncol. 2002 Sep;38(6):610-7
12167440
Cancer Sci. 2006 Sep;97(9):854-60
16805824
Clin Cancer Res. 2007 May 1;13(9):2577-83
17473186
Jpn J Clin Oncol. 2002 Jul;32(7):238-43
12324573
J Clin Endocrinol Metab. 2005 Jan;90(1):463-8
15483076
J Oral Maxillofac Surg. 2007 Feb;65(2):229-36
17236926
Br J Cancer. 2008 Oct 7;99(7):1121-8
18766188
Cancer. 2005 May 1;103(9):1843-9
15772957
Oncology. 1997 Nov-Dec;54(6):463-7
9394842
Br J Cancer. 2000 Sep;83(5):614-9
10944601
Oncol Rep. 2005 Apr;13(4):601-6
15756430
Fundam Clin Pharmacol. 2007 Jun;21(3):231-44
17521292
Clin Cancer Res. 2006 Nov 1;12(21):6444-51
17085658
Gastroenterology. 2009 Apr;136(4):1242-50
19186181
Cancer Sci. 2003 Apr;94(4):365-71
12824906
Lung Cancer. 2002 Jun;36(3):249-55
12009233
PPAR Res. 2008;2008:134059
19125181
Br J Cancer. 2005 Jan 17;92(1):113-9
15583697
Cancer Ther. 2008;6(A):25-34
19079765
Curr Mol Med. 2008 Sep;8(6):562-79
18781963
Clin Cancer Res. 2009 Jan 1;15(1):2-8
19118026
Dig Dis Sci. 2004 Aug;49(7-8):1075-83
15387324